Study Summary
This trial will help determine if suppressing the immune response with either corticosteroids or equine anti-thymocyte globulin therapy helps improve survival rates for children with acute liver failure.
- Hepatic Coma
- Liver Failure, Acute
- Immune Dysregulations
- Liver
Treatment Effectiveness
Effectiveness Progress
Study Objectives
0 Primary · 1 Secondary · Reporting Duration: 180 days
Trial Safety
Safety Progress
Trial Design
3 Treatment Groups
High-dose methylprednisolone
1 of 3
Equine anti-thymocyte globulin
1 of 3
Supportive care
1 of 3
Experimental Treatment
Non-Treatment Group
160 Total Participants · 3 Treatment Groups
Primary Treatment: High-dose methylprednisolone · Has Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age < 65 · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 24th, 2021
Last Reviewed: November 24th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.